- Molecular NameLoteprednol Etabonate
- SynonymLoteprednol
- Weight466.958
- Drugbank_IDDB00873
- ACS_NO82034-46-6
- Show 3D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)3.25
- pkaN/A
- LogD (pH=7, predicted)3.25
- Solubility (experiment)0.005 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)-5.25
- LogSw (predicted, AB/LogsW2.0)0.0
- Sw (mg/ml) (predicted, ACD/Labs)0.0
- No.of HBond Donors1
- No.of HBond Acceptors7
- No.of Rotatable Bonds7
- TPSA99.13
- StatusFDA approved
- AdministrationN/A
- PharmacologyA corticosteroid used in ophthalmology.
- Absorption_valueN/A
- Absorption (description)Very limited systemic absorption, but good absorption at the point of delivery.
- Caco_2N/A
- Bioavailability0.0
- Protein binding90.0
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmLoteprednol etabonate should be metabolized by hydrolysis to the corresponding inactive cortienic acid derivative - deschlormethyl-loteprednol etabonate. The in vitro and in vivo metabolism of loteprednol etabonate indeed yielded mainly this inactive metabolite, which is more hydrophilic and thus readily eliminated from the body. Some of the metabolite deschlormethyl-loteprednol etabonate is further hydrolyzed to cortienic acid
- Half lifeN/A
- ExcretionN/A
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityAdverse effects include abnormal vision / blurring, burning on instillation, chemosis, discharge, dry eyes, epiphora, foreign body sensation, itching, injection, and photophobia.
- LD50 (rat)N/A
- LD50 (mouse)N/A